"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Lars Fruergaard Jørgensen, the chief executive of once-highflying Danish drug manufacturer Novo Nordisk, is stepping down after eight years in the role, the maker of the drugs Ozempic and Wegovy ...

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard ...

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...

Ozempic was approved to treat Type 2 diabetes in 2017, and it’s become increasingly popular among those who don’t have the ...

The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 ...

Costly drugs: The drugs prescribed to fight obesity have been driving up the cost of Medi-Cal, the state program that ...